NanoViricides Inc
NNVC
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
91.5% downsideOvervalued by 91.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $21.80 Million |
|---|---|
| Enterprise Value | $-3,213,234,200,518.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.63 |
| Beta | 1.64 |
| Outstanding Shares | 21,609,000 |
Return
| Return on Equity | -21.73% |
|---|---|
| Return on Assets | -19.47% |
| Return on Invested Capital | -22.18% |
Valuation & Multiples
| P/E Ratio | -3.26 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 1.58 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 35,900▼ 6.27% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 9.57%▼ 6.08% |
|---|---|
| Total Invested | $1.73M▼ 50.64% |
| Investors Holding | 49▲ 4.00% |
ESG Score
No data
About NanoViricides Inc
12 employeesNanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus parti...
Relevant Senate Committees
While advisory, this committee's analysis and scoring of tax legislation directly influence corporate tax structures and capital investment incentives. These policies are crucial for a development-stage company's financial planning and access to capital.
This powerful committee controls taxation, trade, and entitlement spending (e.g., Medicare). Its decisions on corporate tax policy and Medicare drug reimbursement rates directly impact NanoViricides' future profitability and market access for its approved drugs.
This committee directly allocates discretionary federal spending. Its subcommittees determine the precise budgets for the FDA, NIH, and other health agencies, directly impacting research grants and the regulatory environment for NanoViricides.
This committee directly regulates the FDA (drug approval process) and NIH (research funding), which are the most critical external factors for a development-stage biotech company like NanoViricides. It controls the regulatory path and significant funding sources.
This committee's oversight of intellectual property (patents) is absolutely critical for a biotechnology company. IP protection is fundamental to NanoViricides' asset valuation and long-term viability.
NanoViricides' lead drug candidate is for shingles, which primarily affects older adults. This committee's investigations into drug pricing and healthcare for seniors directly impact the potential market and profitability of the company's future products.